Featuring perspectives from Dr Mazyar Shadman, including the following topics:
- The CLL17 trial: Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia (CLL) (0:00)
- The AMPLIFY trial: Fixed-duration acalabrutinib combinations for untreated CLL (5:31)
- Zanubrutinib-based therapy for treatment-naïve CLL (12:32)
CME information and select publications